Case number 2016-1028
Roxane Laboratories, Inc. v. Camber Pharmaceuticals Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | ROXANE LABORATORIES, INC. v. CAMBER PHARMACEUTICALS INC. [OPINION] [nonprecedential] (0) |
| Dec 27, 2016 | 47 | Mandate issued to the United States District Court for the District of New Jersey. Costs taxed in the amount of $467.20. Service as of this date by Clerk of Court. [394400] [JCA] [Entered: 12/27/2016 08:49 AM] (1) |
| Nov 22, 2016 | 46 | Bill of Costs for Appellees Camber Pharmaceuticals Inc. and Invagen Pharmaceuticals Inc.. Service: 11/22/2016 by email. Objection to Bill of Costs due on 12/09/2016. [385356] [Salvatore Guerriero] [Entered: 11/22/2016 10:51 AM] (0) |
| Nov 17, 2016 | 45 | OPINION and JUDGMENT filed. The judgment or decision is: Affirmed. (Nonprecedential Opinion). (For the Court: Lourie,Circuit Judge; Mayer,Circuit Judge and O'Malley,Circuit Judge). [383922] [CAB] [Entered: 11/17/2016 09:07 AM] (15) |
| Oct 7, 2016 | 44 | Submitted after ORAL ARGUMENT by Kenneth G. Schuler for Roxane Laboratories, Inc. and Robert S. Silver for Camber Pharmaceuticals Inc. and Invagen Pharmaceuticals Inc. Panel: Judge: Lourie , Judge: Mayer , Judge: O'Malley. [372601] [JAB] [Entered: 10/07/2016 11:08 AM] (0) |
| Aug 29, 2016 | 43 | Response to oral argument order from the Appellees Camber Pharmaceuticals Inc. and Invagen Pharmaceuticals Inc.. designating Robert S. Silver as arguing attorney. Designated time for argument: 15 minutes. Designated time for rebuttal: 0 minutes. Service of other counsel by Notice of Docket Activity from this entry. [362573] [Robert Silver] [Entered: 08/29/2016 09:54 AM] (0) |
| Aug 26, 2016 | 42 | Response to oral argument order from the Appellant Roxane Laboratories, Inc.. designating Kenneth G. Schuler as arguing attorney. Designated time for argument: 11 minutes. Designated time for rebuttal: 4 minutes. Service of other counsel by Notice of Docket Activity from this entry. [362468] [Kenneth Schuler] [Entered: 08/26/2016 05:25 PM] (0) |
| Aug 19, 2016 | 41 | NOTICE OF CALENDARING. Panel: 1610M. Case scheduled Oct 07, 2016 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, N.W. Washington, DC 20439), Courtroom 201. Response to oral argument order due: 09/15/2016. Counsel should check-in 30 minutes prior to the opening of the session. Please review the Oral Argument Order. [360487] THIS NOTICE APPLIES TO CASE(S): [15-1450, 15-1774, 16-1028, 16-1094] [JAB] [Entered: 08/19/2016 04:15 PM] (0) |
| Jun 22, 2016 | 40 | Notice from Appellees Camber Pharmaceuticals Inc. and Invagen Pharmaceuticals Inc. regarding conflicts with oral argument (Not available during the August court week). Service: 06/22/2016 by email. [345730] [Robert Silver] [Entered: 06/22/2016 11:21 AM] (2) |
| Apr 21, 2016 | 38 | Notice from Appellant Roxane Laboratories, Inc. regarding conflicts with oral argument (Not available during the May court week or on July 5, 2016). Service: 04/21/2016 by email. [328406] [Kenneth Schuler] [Entered: 04/21/2016 11:51 AM] (1) |
| Apr 20, 2016 | 37 | Notice from Appellees Camber Pharmaceuticals Inc. and Invagen Pharmaceuticals Inc. regarding conflicts with oral argument (Scheduling Conflicts). Service: 04/20/2016 by email. [328110] [Robert Silver] [Entered: 04/20/2016 01:06 PM] (2) |
| Apr 19, 2016 | 39 | 6 paper copies of the 3 Volume Appendix [35] received from Appellant Roxane Laboratories, Inc.. [328491] [LAJ] [Entered: 04/21/2016 02:05 PM] (0) |
| Apr 14, 2016 | 36 | Pursuant to Practice Note 34, counsel should advise the clerk of court of scheduling conflicts for the next three court weeks, or thereafter. When filing the notice of conflicts, counsel should docket the Notice of Conflict with Argument Dates event, which is found in the Calendar event category. The notice of conflict with oral argument is due on or before 04/21/2016. [326566] [LN] [Entered: 04/14/2016 04:35 PM] (0) |
| Apr 14, 2016 | 35 | APPENDIX FILED for Roxane Laboratories, Inc. [33]. Number of Pages: 1424. Service: 04/14/2016 by email. Pursuant to Fed. Cir. R. 30(a)(5), filer is directed to file six copies of the brief in paper format. The paper copies of the brief should be received by the court on or before 04/19/2016. [326558] [LN] [Entered: 04/14/2016 04:12 PM] (1424) |
| Apr 14, 2016 | 34 | Statement of Compliance with Fed. Cir. R. 33 for Appellant Roxane Laboratories, Inc. and Appellees Camber Pharmaceuticals Inc. and Invagen Pharmaceuticals Inc.. Service: 04/14/2016 by email. [326514] [Kenneth Schuler] [Entered: 04/14/2016 02:53 PM] (4) |
| Apr 14, 2016 | 33 | TENDERED from Appellant Roxane Laboratories, Inc.. Title: JOINT APPENDIX. Service: 04/14/2016 by email. [326510] [Kenneth Schuler] [Entered: 04/14/2016 02:47 PM] (1424) |
| Apr 6, 2016 | 32 | 6 paper copies of the Reply Brief [31] received from Appellant Roxane Laboratories, Inc.. [324769] [MJL] [Entered: 04/07/2016 11:29 AM] (0) |
| Apr 4, 2016 | 31 | REPLY BRIEF FILED for Appellant Roxane Laboratories, Inc. [30]. Number of Pages: 32. Service: 04/04/2016 by email. Pursuant to Fed. Cir. R. 31(b), filer is directed to file six copies of the brief in paper format. The paper copies of the brief should be received by the court on or before 04/11/2016. Appendix is due 04/14/2016. [324105] [LN] [Entered: 04/05/2016 02:35 PM] (40) |
| Apr 4, 2016 | 30 | TENDERED from Appellant Roxane Laboratories, Inc.. Title: REPLY BRIEF. Service: 04/04/2016 by email. [323805] [Kenneth Schuler] [Entered: 04/04/2016 05:58 PM] (40) |
| Mar 22, 2016 | 29 | 6 paper copies of the Opening Response Brief [28] received from Appellees Camber Pharmaceuticals Inc. and Invagen Pharmaceuticals Inc.. [322149] [LAJ] [Entered: 03/28/2016 02:42 PM] (0) |
| Mar 18, 2016 | 28 | BRIEF FILED for Appellees Camber Pharmaceuticals Inc. and Invagen Pharmaceuticals Inc. [27]. Number of Pages: 57. Service: 03/18/2016 by email. Pursuant to ECF-10, filer is directed to file six copies of the brief in paper format. The paper copies of the brief should be received by the court on or before 03/28/2016. Appellant Roxane Laboratories, Inc. reply brief is due 04/04/2016. [320374] [LN] [Entered: 03/21/2016 02:27 PM] (72) |
| Mar 18, 2016 | 27 | TENDERED from Appellees Camber Pharmaceuticals Inc. and Invagen Pharmaceuticals Inc.. Title: RESPONSE BRIEF. Service: 03/18/2016 by email. [320003] [Robert Silver] [Entered: 03/18/2016 12:59 PM] (72) |
| Mar 16, 2016 | 26 | Amended Certificate of Interest for the Appellees Camber Pharmaceuticals Inc. and Invagen Pharmaceuticals Inc.. Service: 03/16/2016 by email. [319186] [Robert Silver] [Entered: 03/16/2016 02:34 PM] (3) |
| Mar 9, 2016 | 24 | REMINDER: All counsel of record are reminded of their responsibility per Fed. Cir. R. 47.4(a), Fed. Cir. R. 47.3 and ECF-2(E) to promptly submit an amended Certificate of Interest (COI) and/or Entry of Appearance (EOA) as information changes during the pendency of the appeal. Failure to comply with these Rules may delay the timely processing of your case or result in adverse action. [317124] [LN] [Entered: 03/09/2016 12:11 PM] (0) |
| Mar 9, 2016 | 25 | Amended Certificate of Interest for the Appellant Roxane Laboratories, Inc.. Service: 03/09/2016 by email. [317306] [Kenneth Schuler] [Entered: 03/09/2016 05:48 PM] (3) |
| Feb 9, 2016 | 23 | 6 paper copies of the Opening Brief [22] received from Appellant Roxane Laboratories, Inc.. [309947] [LAJ] [Entered: 02/10/2016 11:45 AM] (0) |
| Feb 5, 2016 | 22 | BRIEF FILED for Appellant Roxane Laboratories, Inc. [21]. Number of Pages: 66. Service: 02/05/2016 by email. Pursuant to ECF-10, filer is directed to file six copies of the brief in paper format. The paper copies of the brief should be received by the court on or before 02/16/2016. Appellees Camber Pharmaceuticals Inc. and Invagen Pharmaceuticals Inc. brief is due 03/21/2016. [309198] [JCA] [Entered: 02/08/2016 10:51 AM] (112) |
| Feb 5, 2016 | 21 | TENDERED from Appellant Roxane Laboratories, Inc.. Title: OPENING BRIEF. Service: 02/05/2016 by email. [309064] [Kenneth Schuler] [Entered: 02/05/2016 07:55 PM] (112) |
| Nov 23, 2015 | 20 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellant Roxane Laboratories, Inc.. Service: 11/23/2015 by email. [290970] [Kenneth Schuler] [Entered: 11/23/2015 12:36 PM] (3) |
| Nov 20, 2015 | 19 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellees Camber Pharmaceuticals Inc. and Invagen Pharmaceuticals Inc.. Service: 11/20/2015 by email. [290401] [Robert Silver] [Entered: 11/20/2015 11:43 AM] (3) |
| Oct 30, 2015 | 18 | ORDER granting motion to terminate cross/consolidated appeal [17] filed by Cross-Appellants Camber Pharmaceuticals Inc. and Invagen Pharmaceuticals Inc. in 16-1028. The revised official caption is reflected in the order. Issued as a mandate as to 16-1030 only. Service as of this date by Clerk of Court. [284915] [16-1028, 16-1030] [LN] [Entered: 10/30/2015 03:07 PM] (2) |
| Oct 30, 2015 | 17 | MOTION of Cross-Appellants Camber Pharmaceuticals Inc. and Invagen Pharmaceuticals Inc. to terminate cross/consolidated appeal. Response/Opposition is due 11/12/2015 [Consent: unopposed]. Service: 10/30/2015 by email. [284828] [Robert Silver] [Entered: 10/30/2015 12:14 PM] (6) |
| Oct 19, 2015 | 16 | Corrected Certificate of Interest for the Appellant Roxane Laboratories, Inc.. Service: 10/19/2015 by email. [281490] [Kenneth Schuler] [Entered: 10/19/2015 03:23 PM] (3) |
| Oct 19, 2015 | 15 | Docketing Statement for the Appellant Roxane Laboratories, Inc.. Service: 10/19/2015 by email. [281487] [Kenneth Schuler] [Entered: 10/19/2015 03:14 PM] (4) |
| Oct 16, 2015 | 14 | Entry of appearance for Pei-Ru Wey as of counsel for Appellees Camber Pharmaceuticals Inc. and Invagen Pharmaceuticals Inc.. Service: 10/16/2015 by email. [281051] [Pei-Ru Wey] [Entered: 10/16/2015 02:15 PM] (3) |
| Oct 16, 2015 | 13 | Entry of appearance for Salvatore Guerriero as of counsel for Appellees Camber Pharmaceuticals Inc. and Invagen Pharmaceuticals Inc.. Service: 10/16/2015 by email. [281048] [Salvatore Guerriero] [Entered: 10/16/2015 02:11 PM] (3) |
| Oct 16, 2015 | 12 | Docketing Statement for the Appellees Camber Pharmaceuticals Inc. and Invagen Pharmaceuticals Inc.. Service: 10/16/2015 by email. [281047] [Robert Silver] [Entered: 10/16/2015 02:08 PM] (4) |
| Oct 16, 2015 | 11 | Certificate of Interest for the Appellees Camber Pharmaceuticals Inc. and Invagen Pharmaceuticals Inc.. Service: 10/16/2015 by email. [281044] [Robert Silver] [Entered: 10/16/2015 02:07 PM] (3) |
| Oct 16, 2015 | 10 | Entry of appearance for Robert S. Silver as principal counsel for Appellees Camber Pharmaceuticals Inc. and Invagen Pharmaceuticals Inc.. Service: 10/16/2015 by email. [281042] [Robert Silver] [Entered: 10/16/2015 02:06 PM] (3) |
| Oct 13, 2015 | 9 | **TEXT ONLY** ORDER granting motion to extend time to file appellant's principal brief [8] filed by Appellant Roxane Laboratories, Inc. Brief due 02/05/2016. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [279786] [SJ] [Entered: 10/13/2015 12:13 PM] (0) |
| Oct 8, 2015 | 8 | MOTION of Appellant Roxane Laboratories, Inc. to extend the time to 02/05/2016 at 11:59 pm to file the appellant/petitioner's principal brief. Response/Opposition is due 10/22/2015 [Consent: unopposed]. Service: 10/08/2015 by email. [278987] [Kenneth Schuler] [Entered: 10/08/2015 04:03 PM] (7) |
| Oct 8, 2015 | 7 | Entry of appearance for Gregory K. Sobolski as of counsel for Appellant Roxane Laboratories, Inc.. Service: 10/08/2015 by email. [278975] [Gregory Sobolski] [Entered: 10/08/2015 03:52 PM] (3) |
| Oct 8, 2015 | 6 | Entry of appearance for Robert J. Gajarsa as of counsel for Appellant Roxane Laboratories, Inc.. Service: 10/08/2015 by email. [278934] [Robert Gajarsa] [Entered: 10/08/2015 03:11 PM] (3) |
| Oct 8, 2015 | 5 | Entry of appearance for Marc N. Zubick as of counsel for Appellant Roxane Laboratories, Inc.. Service: 10/08/2015 by email. [278926] [Marc Zubick] [Entered: 10/08/2015 03:07 PM] (3) |
| Oct 8, 2015 | 4 | Certificate of Interest for the Appellant Roxane Laboratories, Inc.. Service: 10/08/2015 by email. [278911] [Kenneth Schuler] [Entered: 10/08/2015 02:57 PM] (3) |
| Oct 8, 2015 | 3 | Entry of appearance for Kenneth G. Schuler as principal counsel for Appellant Roxane Laboratories, Inc.. Service: 10/08/2015 by email. [278900] [Kenneth Schuler] [Entered: 10/08/2015 02:52 PM] (3) |
| Oct 7, 2015 | 2 | Note to file: The following cases are associated:16-1028 Lead with 16-1030 Cross-Appeal. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [278403] [16-1028, 16-1030] [FMS] [Entered: 10/07/2015 01:30 PM] (0) |
| Oct 7, 2015 | 1 | Appeal docketed. Received:. [278318]Entry of Appearance due 10/21/2015. Certificate of Interest is due on 10/21/2015. Docketing Statement due 10/21/2015. Appellant/Petitioner's brief is due 12/07/2015. [FMS] [Entered: 10/07/2015 10:38 AM] (53) |
